During the last session, Bicara Therapeutics Inc (NASDAQ:BCAX)’s traded shares were 0.31 million. The 52-week high for the BCAX share is $28.09, that puts it down -109.63 from that peak though still a striking 17.16% gain since the share price plummeted to a 52-week low of $11.10. The company’s market capitalization is $729.17M, and the average intraday trading volume over the past 10 days was 0.49 million shares, and the average trade volume was 445.47K shares over the past three months.
Bicara Therapeutics Inc (NASDAQ:BCAX) trade information
The stock’s 5-day price performance is 1.21%, and it has moved by 8.41% in 30 days. The short interest in Bicara Therapeutics Inc (NASDAQ:BCAX) is 5.05 million shares and it means that shorts have 15.48 day(s) to cover.
The consensus price target of analysts on Wall Street is $35, which implies an increase of 61.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $35 and $35 respectively. As a result, BCAX is trading at a discount of -161.19% off the target high and -161.19% off the low.
While earnings are projected to return 55.31% in 2025, the next five years will return 10.52% per annum.
BCAX Dividends
Bicara Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders
Bicara Therapeutics Inc insiders own 0.43% of total outstanding shares while institutional holders control 86.06%, with the float percentage being 86.43%.
Also, the Mutual Funds coming in first place with the largest holdings of Bicara Therapeutics Inc (BCAX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 636.55 shares. This amounts to just over 1.17 percent of the company’s overall shares, with a $8.53 million market value. The same data shows that the other fund manager holds slightly less at 589.03, or about 1.08% of the stock, which is worth about $7.89 million.
